Shares of Hims & Hers Health jumped more than 8% to approximately $26 on Thursday after the U.S. Food and Drug Administration announced it would begin a formal review process that could eventually alter the regulatory standing of several wellness peptides used in compounding pharmacies — a development the market interpreted as a meaningful signal for companies with exposure to the compounding space.
The move triggered an immediate analyst response, with Bank of America raising its price objective for the company shortly after the announcement.
What the FDA actually announced
The FDA confirmed it will convene its Pharmacy Compounding Advisory Committee on July 23 and 24 to evaluate whether multiple peptide-related bulk drug substances should be considered for possible inclusion on what is known as the 503A bulks list — a designation that would affect how those substances can be used in compounding pharmacies operating under that regulatory framework.
The substances under review are BPC-157, KPV, TB-500, MOTs-C, emideltide, semax and epitalon — a group of compounds that have attracted growing interest in the wellness and longevity space but currently face restrictions on their compounding and commercial use. Ahead of the July meetings, the FDA also opened a public comment docket, with submissions due in early July.
Bank of America raises its price target
Following the announcement, Bank of America lifted its price objective for Hims & Hers Health to $25 from a prior target of $21, while maintaining a neutral rating on the stock. The firm cited higher peer valuation multiples across the sector and increased long-term optionality tied to the emerging peptide-related developments as the primary drivers of the adjustment.
The target multiple was also revised upward, moving from approximately 21.5x to roughly 25.5x, reflecting both a broader sector re-rating and what analysts described as potential strategic upside for companies with compounding infrastructure already in place.
A procedural step, not a commercial unlock
Despite the enthusiasm reflected in Thursday’s share price movement, Bank of America was deliberate in framing the FDA’s announcement as an early-stage procedural development rather than a regulatory green light for compounding or mass commercialization of the peptides in question.
The analysts described the move as incrementally constructive for long-term optionality but not a near-term earnings driver, noting clearly that the review process could, in theory, expand potential compounding pathways and create new addressable demand categories — but that the ultimate outcome of those July meetings remains genuinely uncertain.
The firm was equally direct in flagging what remains unresolved. Whether the wellness peptides under review will ultimately be permitted for compounding or broader commercialization is still an open question, and the current announcement does not change any existing restrictions. Any meaningful commercial impact would depend entirely on what the FDA decides following the committee review.
What this means specifically for Hims & Hers
For Hims & Hers, the strategic interest in the FDA’s review stems largely from the company’s existing compounding infrastructure. The company has built out significant operational capacity tied to GLP-1 related compounding in recent years, and if future FDA rulings prove favorable for peptide compounding, there is a credible case that portions of that existing capacity could be repurposed toward peptide-based offerings. That kind of operational pivot would potentially help offset fixed costs already embedded in the company’s operating assumptions — a meaningful consideration for long-term financial modeling even if the near-term picture remains unchanged.
Bank of America’s analysis characterized Thursday’s development as adding strategic optionality rather than delivering immediate financial impact, a framing that captures the nuanced nature of a regulatory process that still has several steps and months ahead of it before any outcomes are known.
The July committee meetings will be the next key milestone to watch for investors tracking this story.
Source: MyProactive / Bank of America